Palvella Therapeutics, Inc. (PVLA) Investor Relations Documents

Palvella Therapeutics, Inc. (PVLA) investor relations documents from the company's IR site: 7 presentations, 19 press releases; latest deck 2026-07-14. Read in-app with summaries. First-party data.

Corporate Presentation: Palvella Therapeutics is a biopharma company developing QTORIN-based topical therapies for rare skin diseases, targeting 1H 2027 approval for microcystic LMs.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releasePalvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-08-04Press releasePalvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-30Press releasePalvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop o
2026-07-28Press releasePalvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 20
2026-07-14PresentationCorporate Presentation
2026-06-30Press releasePalvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A
2026-06-29Press releasePalvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatmen
2026-06-22Press releaseFDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
2026-06-03Press releasePalvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malform
2026-06-02Press releasePalvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
2026-05-27Press releasePalvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Pr
2026-05-20PresentationView Presentation
2026-05-15Press releasePalvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformat
2026-05-04Press releasePalvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin fo
2026-04-20Press releasePalvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the Internati
Press releasePalvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
2026-03-27Press releasePalvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at t
Press releasePalvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 3
2026-02-24PresentationPresentation
2026-02-24Press releasePalvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anh
2026-02-23Press releasePalvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.
2026-01-09Press releasePalvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform
2025-12-15PresentationPresentation
2025-11-05PresentationPresentation
2024-10-23PresentationView Poster
2024-10-23PresentationView Poster

PVLA overview · PVLA earnings · PVLA financials · PVLA KPIs · PVLA documents · PVLA ownership · PVLA peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.